Bruton’s tyrosine kinase (BTK) is at the core of present day treatment in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) which in turn is redefining first line and relapsed ...

Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the abstracts of two clinical studies ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharm ...

BeOne Medicines’ sonrotoclax receives US FDA approval as first and only BCL2 inhibitor for R/R mantle cell lymphoma: San Carlos, California Saturday, May 16, 2026, 14:00 Hrs [IS ...

Detailed price information for Beone Medicines Ltd (ONC-Q) from The Globe and Mail including charting and trades.

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted ...

Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company’s targeted protein degradation platform, in relapsed or refractory multiple ...

Eli Lilly and Company (NYSE: LLY) today announced the details of presentations from across its oncology portfolio at the ...

Communication gaps persisted despite shared decision-making norms, with limited patient-perceived comprehension and ...

Taiwanese streamer Catchplay and production outfit Screenworks Asia are making a big push into microdrama in partnership with ...

Zydus Pharmaceuticals - Read all the latest news headline updates on Zydus Pharmaceuticals. Get all the Zydus Pharmaceuticals breaking news updates, videos, photostories and more at Business Standard.